Haemonetics Gains After Update on CSL Supply Deal
Haemonetics (HAE:NYSE) rose approximately 14% in premarket trading after announcing an update regarding its supply agreement with CSL Limited. The Australian biopharmaceutical company plans to deploy Haemonetics' devices across its U.S. plasma collection centers, as outlined earlier. The development reinforces the ongoing partnership between Haemonetics and CSL, which is a major player in global plasma-derived therapies. This move could lead to increased demand for Haemonetics’ equipment used in blood processing and plasma collection. Investors reacted positively to the news, signaling confidence in the company's role within critical healthcare infrastructure.
